Loop interactions and dynamics tune the enzymatic activity of the human histone deacetylase 8. by Kunze, MB et al.
Loop Interactions and Dynamics Tune the Enzymatic Activity of the
Human Histone Deacetylase 8
Micha B. A. Kunze,† David W. Wright,‡ Nicolas D. Werbeck,† John Kirkpatrick,† Peter V. Coveney,*,‡,§
and D. Flemming Hansen*,†
†Institute of Structural and Molecular Biology, Division of Biosciences, University College London, Gower Street, London WC1E
6BT, United Kingdom
‡Centre for Computational Science, Department of Chemistry, University College London, Gordon Street, London WC1H 0AJ,
United Kingdom
§Yale University, School of Medicine, P.O. Box 208017, New Haven, Connecticut 06520-8017, United States
*S Supporting Information
ABSTRACT: The human histone deacetylase 8 (HDAC8) is
a key hydrolase in gene regulation and has been identiﬁed as a
drug target for the treatment of several cancers. Previously the
HDAC8 enzyme has been extensively studied using bio-
chemical techniques, X-ray crystallography, and computational
methods. Those investigations have yielded detailed informa-
tion about the active site and have demonstrated that the
substrate entrance surface is highly dynamic. Yet it has
remained unclear how the dynamics of the entrance surface
tune and inﬂuence the catalytic activity of HDAC8. Using long time scale all atom molecular dynamics simulations we have
found a mechanism whereby the interactions and dynamics of two loops tune the conﬁguration of functionally important
residues of HDAC8 and could therefore inﬂuence the activity of the enzyme. We subsequently investigated this hypothesis using
a well-established ﬂuorescence activity assay and a noninvasive real-time progression assay, where deacetylation of a p53 based
peptide was observed by nuclear magnetic resonance spectroscopy. Our work delivers detailed insight into the dynamic loop
network of HDAC8 and provides an explanation for a number of experimental observations.
■ INTRODUCTION
Post-translational histone modiﬁcations are essential cellular
processes that regulate the accessibility of DNA to the cell’s
transcriptional apparatus. One such modiﬁcation is acetylation
of lysine side-chains that renders these neutral in charge and
thereby alters the electrostatic interactions between, for
example, histone tails and DNA or bromodomains. As
important as the enzymes that generate the post-translational
modiﬁcations are the enzymes that reverse them. One class of
enzymes that mediate the reversal of histone modiﬁcations is
comprised of the histone deacetylases (HDACs),1 which
catalyze deacetylations of acetylated lysine side-chains in
histones1 and other cellular proteins.2 Deacetylation of histone
tails leads to a condensed and inaccessible chromatin structure
at the site of modiﬁcation.3 Besides histones, (de)acetylations
are now known to regulate a large body of enzymes in the
cell,4,5 thus making HDACs key entities in the regulation of
eukaryotic cells.6,7 In particular, HDACs are often up-regulated
in cancers,8 and the inhibition of HDACs is now believed to be
a promising way to improve the treatment of several cancers.9
Verinostat (suberoylanilide hydroxamic acid; SAHA) is one
such HDAC inhibitor approved by the FDA for the treatment
of T-cell lymphoma.
The family of human HDACs encompasses at least 11
classical zinc-dependent isoforms with various cellular
functions9 and can be categorized into four major classes
based on phylogenetic analysis and sequence similarity. For
example, the classical class I HDACs include isoforms HDAC1,
HDAC2, HDAC3, and HDAC8, which is the focus of this
study. Crystal structures of HDACs and HDAC8 in particular
have yielded detailed insight into the structure and conforma-
tional diversity of this protein10−13 when bound to inhibitors
and substrates, whereas only one structure of HDAC8 without
a binding partner is available.11 Crystal structures of HDAC8
complexed with inhibitors show diﬀerent conformations of the
HDAC8 surface, and computational studies have shown that
HDAC8 can interconvert between diﬀerent entrance topologies
on the nanosecond time scale.14−18 Thus, the surface around
the entrance tunnel to the active site is malleable, thereby
allowing for interaction with diﬀerent binding partners (Figure
1a).
Despite the malleability of the surface that surrounds the
entrance to the active site tunnel, crystal structures of HDAC8
exhibit a structurally highly conserved binding conﬁguration
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formed by residues Tyr100 and Asp101,12 which we will refer
to as the binding rail (Figure 1b). For example, Vannini et al.
showed that Asp101 forms hydrogen bonds with the backbone
of a substrate thereby positioning and stabilizing the substrate
for the deacetylation reaction.10 When a substrate-like ligand is
bound, Tyr100 and Asp101 stabilize the binding via stacking of
aromatic groups or hydrogen bonds, respectively. The binding
rail residues show this conformation in every available crystal
structure where electron density is not missing for these
residues. Moreover, mutating Asp101 to Ala renders HDAC8
inactive, which attests to the importance of this residue and the
binding rail in general for the catalytic activity.10
The binding rail is located in the L2 loop (Figure 1). The L2
loop, which consists of residues 83−108, has two parts: residues
83−92 that are distal to the entrance tunnel and residues 93−
108 that are proximal and include the binding rail, Tyr100 and
Asp101. The distal part of the L2 loop is found in diﬀerent
conformations depending on the inhibitor bound, although
electron density is often lacking for this part of the loop. In
some crystal structures almost the entire L2 loop is missing
electron density (PDB codes 3SFH, 1VKG) probably because
no favorable interactions between the binding rail and the
inhibitors can be formed. The ligands in these structures are
not substrate-like and cannot form hydrogen bonds with
Asp101 nor can they π-stack with Tyr100. The HDAC8
structure reported without a ligand bound shows no electron
density for residues 85−103 (PDB code 3F07 chain C). Thus,
previous studies suggest that the L2 loop is highly dynamic, the
weaker the interaction between the ligand and the binding rail
the more dynamic the loop. Moreover, in some crystal
structures the L2 loop is involved in symmetry related crystal
contacts, which aﬀects the B-factors in this region, further
confounding a concise interpretation of the loop ﬂexibility from
crystal structures alone.
The L1 loop, which spans residues 31−35 (Figure 1a), is also
located in the vicinity of the entrance to the catalytic site. The
L1 loop is directly above an internal cavity, which is believed to
play a role in the catalytic mechanism18 by functioning as an
exit tunnel for the acetate product after catalysis. As for the L2
loop described above, the L1 loop is found in very diﬀerent
conformations in diﬀerent crystal structures (Figure 1a).
Speciﬁcally, the Cα position of Lys33 in this loop deviates by
more than 0.5 nm when bound to diﬀerent inhibitors (PDB
codes 1T69 and 1T64), demonstrating its ﬂexibility and ability
to undergo large-scale motions. Both, the L1 and L2 loops are
regions of the highest sequence variation among the class I
HDACs.
Correlation between HDAC8 activity and loop ﬂexibility has
been suggested previously by Somoza et al.12 and Dowling et
al.,11 among others. In particular, it was shown that a zinc ion
can bind to the distal part of the L2 loop and thereby stabilize
its conformation.11 This stabilization down-regulates the
activity, which demonstrates that ﬂexibility is important for
function.11 Moreover, a recent crystal structure and study of
HDAC319 shows strong evidence that ﬂexibility of both the L1
and L2 loops is essential for catalytic function of HDAC3.
HDAC3 and HDAC8 are both class I histone deacetylases, and
they have high sequence and structural similarity (41%
sequence identity and structure similarity Z-score of 55.8 for
crystal structures 1T64 and 4A69), which indicate that
ﬂexibility of the L1 and L2 loops is also important for
HDAC8 and possibly for class I HDACs in general.
A mechanism describing how the loop dynamics and
diﬀerent conformations tune the activity of HDACs and the
involvement of dynamics in the catalytic cycle is, to the best of
our knowledge, not present in the literature. To explore these
questions and the possible function of the malleable surface we
ﬁrst carried out two 1.1 μs fully atomistic molecular dynamics
(MD) simulations of HDAC8 (with and without inhibitor) in
explicit solvent followed by a 13.2 μs simulation of HDAC8 on
the Anton supercomputer.20,21 As these simulations showed
interesting conformational transitions we designed mutants to
interfere with such transitions and measured the resulting
change in enzymatic activity. We employed a ﬂuorogenic assay
as well as a novel real-time progression NMR assay we have
developed, where we use part of the acetylated N-terminal tail
of p53 as a substrate. Overall, our data indicate that
interconversions between diﬀerent L1 and L2 loop conforma-
tions may be key for the enzymatic activity.
■ RESULTS AND DISCUSSION
MD Simulation of the Free HDAC8 Shows Population
of Distinct States. As expected from the previously solved
structures and experimental results, the simulation of free
HDAC8 shows that the surface in the vicinity of the entrance to
the catalytic site is very ﬂexible and in particular the L1 and L2
loops of HDAC8 interconvert between diﬀerent states (Figure
2), some of which are closely related to diﬀerent crystal
structures (Figure S1). For example, in one of the L1 loop
conformations present during the simulation an extra cavity and
a large groove become accessible, as has been observed in
crystal structures with diﬀerent ligands10,12 and in other
computational studies.14,15 For the L2 loop, the binding rail
has two distinct conformations, which we will refer to as ‘in’
and ‘out’ (colored light- and dark-green, respectively, in Figure
2a). In the ‘in’ conformation Tyr100 and Asp101 build a rail
toward the catalytic site as observed in crystal structures10,13
(Figures 1b and S1d and Video S1), which has been attributed
to substrate binding and positioning (Figure 1b).10 On the
contrary, in the ‘out’ conformation, the binding rail residues
100 and 101 are oriented away from the entrance to the
catalytic site. The interconversion between ‘in’ and ‘out’
conformations takes place at Tyr100, as shown in the analysis
of the backbone Φ angle (Figure 2b). The Φ angle is larger
than −60° in the ‘in’ conformation, as illustrated in Figure S1d,
where, for example, the binding rail is mainly in the ‘in’
conformation between 800 and 1000 ns.
Figure 1. (a) Overlay of available crystal structures of HDAC8
represented as ribbons. Structural variation of the L1 and L2 loops is
highlighted with a dashed line. (b) Ribbon representation of HDAC8
Tyr306Phe (PDB code 2V5W) in gray bound to a cleavable substrate
in green licorice. Insert shows a zoom into the interaction of the
binding rail residue Asp101 and the substrate backbone.
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Since, as outlined above, the binding rail is very important for
function, we examined the simulations with the aim of revealing
possible mechanisms that interfere with the binding rail
conformation. We observed three features of the L1 and L2
dynamics that can be represented by three microkinetic
processes, that is, (1) the binding rail ﬂips between ‘in’ and
‘out’ conformations, (2) L1:L2 interaction, dominated by salt-
bridge formation between Lys33 of L1 and the triple Asp repeat
of L2 (residues 87−89), and (3) formation of a helix in the L2
loop. These processes seem to be correlated (Figure 2b), and
hence we divide the trajectory into three consecutive states: f1,
f2 and f3, which each show a characteristic pattern regarding
the microkinetic processes.
The binding rail initially starts in the ‘in’ conformation and
ﬂips to the ‘out’ conformation after a couple of nanoseconds.
After the initial ﬂipping out, the binding rail is only found in its
‘out’ conformation for the next 420 ns. This behavior of the
binding rail appears to be cooperative with conformational
changes along the L2 loop from Tyr100 toward the triple Asp
repeat and the formation of salt bridges between the triple Asp
repeat of the L2 loop and the Lys33 of the L1 loop,
characteristic for the L1:L2 interaction. Thus, the binding rail is
trapped in the ‘out’ state between 160 and 420 ns where the L1
and L2 loop interact (Video S1). These electrostatic
interactions are not present in the subsequent f3 state, which
allows the L2 loop to adopt conformations where the binding
rail becomes loose and can ﬂip between the ‘in’ and ‘out’
conformations. Thus, after 420 ns of simulation time, when
reaching the f3 state, we see several ‘in’ to ‘out’ and ‘out’ to ‘in’
ﬂipping events (Figure S1d).
It seems that the binding rail behavior can be steered by the
presence or absence of the L1:L2 interactions. We observe a
number of transitions between the microkinetic states, which
suggests that the energy landscape between the states is
shallow. Hence, a small perturbation to the energy landscape,
such as point mutations or binding of small regulators and
inhibitors could stabilize one of the states and thereby shift the
populations, as has been shown for low-lying thermally excited
states in other proteins.22−24 To further investigate a possible
correlation between the binding rail and the L1:L2 interaction,
we perturbed the energy landscape of HDAC8 by simulating
the response to a small and ﬂexible HDAC inhibitor, SAHA,
followed by the experimental investigation of the L1:L2
interactions using point mutations assessed by in vitro
biochemical assays. Overall, we seek to characterize the
response of the interactions, dynamics, and structure to
perturbations and relate this to the catalytic function of
HDAC8.
MD Simulation of the HDAC8:SAHA Complex. The
structure of the HDAC8:SAHA complex is shown in Figure 3a.
Flexible behavior of the ligand and the loops at the entrance
surface in the HDAC8:SAHA complex is expected, since
crystallographic B-factors are large in these regions, while high
R values are also observed for this ligand (Video S2).
Again we decomposed the trajectory into the three
microkinetic processes (Figure 3b), clearly revealing two
distinct states, which we name i1 and i2. In the i1 state, after
the initial interaction of the binding rail with SAHA is lost, the
aromatic ring of SAHA adopts a number of binding modes
diﬀerent from the crystal structure, although the hydroxamate
group always remains bound to the catalytic zinc (Video S2).
Overall, in the i1 state SAHA can adopt a conformation where
its aromatic cap group is buried in a pocket that becomes
accessible in the vicinity of the entrance tunnel and the L1 loop.
In this conformation, where SAHA is buried in the pocket at
the L1 loop, Lys33 exhibits frequent electrostatic contacts with
the triple Asp repeat of the distal part of the L2 loop, while the
binding rail is in the ‘out’ conformation, preventing any
contacts with the inhibitor. Thus, the frequent interactions of
L1 and L2 loops prevent helix formation and keep the binding
rail trapped in its ‘out’ conformation. This is the same
mechanism that we observed for the free form in the f2 state,
where the distal part of the L2 loop interacts with the L1 loop.
In the i2 state, which is reached after ∼500 ns, the L1:L2
interactions are less frequent, allowing the formation of a helix
in the L2 loop (residues 93−97). During the i2 to i1 transition
Figure 2. (a) Ribbon representation of snapshots during the
simulation showing the ‘in’ (pale colors) and ‘out’ (dark colors)
conformation of the binding rail (green residues). Microkinetic
processes including their localization are annotated. (b) Microkinetic
processes and states over the simulation time: (i) binding rail ﬂips,
measured via Φ of Tyr100 (ii) L1:L2 salt-bridge formation between
Lys33 and Asp87−89 measured using a Lys Nζ-Asp Oδ distance cutoﬀ
of 0.35 nm (iii) presence of an α-helix at residues 93−97 as calculated
by STRIDE.
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at 780 ns the L1:L2 interactions again increase, coinciding with
an unraveling of the helix.
The L1:L2 interactions in the HDAC8:SAHA complex are
much more pronounced than in free HDAC8, trapping the
binding rail in its ‘out’ conformation throughout the simulation.
Nevertheless, it is clear that the states sampled by the perturbed
form (HDAC8:SAHA) and the free form of HDAC8 show
many similarities, in particular, the f2 and the i1 state have
many common features, such as the conformation of the L1
loop and the formation of salt bridges between Lys33 and the
triple Asp repeat in the L2 loop. Hence, we conclude that the
mechanism of L1:L2 interaction steering the binding rail
behavior we observe is robust and can be triggered by small
perturbations such as the binding of a small molecule.
In the 1.1 μs duration simulations, we have only observed a
few transitions between the states. To enhance the sampling of
the transitions we used metadynamics simulations. However,
these proved unsuccessful as using collective variables such as
the L1−L2 loop distance and backbone angle of Tyr100 did not
enhance sampling of the transitions. We infer that there are
unknown processes transverse to the chosen collective variables
that limit the sampling rate and lead to strong hysteresis.
As an alternative route to improve the sampling of the state
transitions, we used the Anton supercomputer to carry out a
much longer, unbiased, MD simulation. While simulating free
HDAC8 for 13.2 μs did not yield proportionally more sampling
of the state transitions, the longer simulation conﬁrms our
previous observation that L1:L2 interactions steer the binding
rail backbone conformation (Figure S2), and we can see several
states where there are L1:L2 interactions present or absent.
Since these microkinetic processes steer a functionally
important part of the protein, we hypothesize that the observed
processes play a role in the catalytic cycle of HDAC8. It is
unfortunately not feasible to simulate the whole catalytic
mechanism including binding, cleaving of substrate and product
egression. Even obtaining statistically robust measurements of
the loop state transition is barely achievable, as we have shown
using Anton. Given these limitations, only experimental
evidence can substantiate this hypothesis. Hence, we expressed
HDAC8 mutants in which the L1:L2 interactions are altered
and measured their activity.
Enzymatic Activity of HDAC8 Mutants. Salt-bridge
formation between the L1 and L2 loop is characteristic of the
L1:L2 interaction, which led us to design three mutants that
change the charges of the loops in a systematic manner and
thereby modulate the L1:L2 interactions. The three mutants
are: Lys33Glu; Asp87Arg/Asp88Arg/Asp89Arg, which we
abbreviate as Asp87−89Arg; and a charge-swap mutant
Lys33Glu/Asp87−89Arg. We ﬁrst assessed the enzymatic
activity of the wild-type HDAC8 and these mutants with a
ﬂuorogenic assay using Boc-Lys(Ac)-7-amino-4-methylcoumar-
in (MAL) as a substrate.25 The wild-type HDAC8 has a kcat/Km
of 38 ± 4 M−1 s−1 for the MAL substrate while, as shown in
Table 1, mutating Lys33 to Glu leaves the enzyme with only 8%
activity and mutation of the three Asp residues 87−89 to Arg
results in 54% residual activity. Now, if the L1:L2 interaction
were irrelevant for enzymatic activity, then one would expect
that the charge-swap mutant Lys33Glu/Asp87−89Arg should
have a relative activity given by the product of the two
individual relative activities of the mutants, Lys33Glu and
Asp87−89Arg. Interestingly, the charge-swap mutant shows
15% of wild-type activity, which is signiﬁcantly larger than what
would be expected in a model where the enzyme activity were
independent of the Lys33:Asp87−89 interaction.
Figure 3. States of the L1 and L2 loop conformations when interacting
with SAHA (chemical structure shown in the insert). (a):
HDAC8:SAHA complex snapshot of the simulation with SAHA
(licorice) and HDAC8 (gray cartoon) where the binding rail is in its
‘out’ conformation. Positions of Lys33, Asp87−89, Tyr100, and
Asp101 are illustrated with colored spheres. (b): Microkinetic
processes over the simulation time as deﬁned in Figure 2: (i) Φ
angle of Tyr100, indicating binding-rail conformation; (ii) L1:L2 salt
bridge presence between Lys33 and Asp87−89; (iii) presence of an α-
helix at residues 93−97.
Table 1. Relative Enzymatic Activity of HDAC8 Mutants
variant MAL assay [relative] NMR p53 assay [relative]
WT 100% 100%
Lys33Glu 8% ± 2% 1.8% ± 0.2%
Asp87−89Arg 54% ± 7% 10.1% ± 0.5%
Lys33Glu/Asp87−89Arg 15% ± 3% 11.5% ± 0.5%
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Although the three mutations alter the L1:L2 interaction,
they could also aﬀect substrate binding and cause other changes
due to the change of charge and steric eﬀects. Speciﬁcally,
Lys33 is not far from the binding rail itself, and mutation of this
residue could directly interfere with substrate binding. More-
over, the MAL substrate is by no means a perfect mimic of a
natural substrate since the methylcoumarin ﬂuorophore is
attached directly to the C-terminus of the acetylated lysine,
which like the substrate in the crystal structure 2V5W probably
points directly toward Lys33. Also, the amino acids introduced
by mutation (up to four) are of diﬀerent sizes to those in the
wild-type enzyme; it is therefore very likely that we observe a
combination of an alteration of the L1:L2 interaction together
with other secondary eﬀects.
To address these issues and to conﬁrm that the L1:L2
interaction generally tunes the enzymatic activity of HDAC8,
we established a real-time NMR assay with a more natural-like
substrate. In this assay the activity of the HDAC8 mutants was
measured against an acetylated lysine embedded in a 21 amino
acid residue peptide based on a part of the N-terminal tail of
the tumor suppressor p53 GSHLKSKKGQSTSRHK-K(Ac)-
LMFK, where the acetylated Lys (K(Ac)) corresponds to the
382 position in p53. Monitoring the amount of substrate and
product over time followed by ﬁtting to the Michaelis−Menten
diﬀerential equations allows us to determine kcat/Km values for
HDAC8 with this natural-like substrate (see Supporting
Information).
For wild-type HDAC8, kcat/Km = 289 ± 6 M
−1 s−1 in the
real-time p53 based assay, which is approximately one-third of
that reported for the Fluor-de-Lys assay (BIOMOL)
previously.11 As shown in Table 1, the activity of the Lys33Glu
mutant is minimal, with only ∼2% of the wild-type activity. The
Asp87−89Arg mutant and the charge-swap mutant Lys33Glu/
Asp87−89Arg show very similar kcat/Km values, at ∼10% of the
wild-type activity. Hence, for this more natural-like substrate
the rescue eﬀect resulting from reintroducing attracting charges
on the L1 and L2 loops is larger than in the ﬂuorogenic assay
and yields an activity which exceeds that of the Asp87−89Arg
mutation alone. Again, the importance of the Lys33:Asp87−89
interaction for activity is further emphasized as the product of
the relative activity of the two individual mutants, 0.018 ×
0.101 ≈ 0.002, is signiﬁcantly lower than the relative activity of
the charge-swap Lys33Glu/Asp87−89Arg mutant, 0.115.
The inﬂuence on activity and the rescue eﬀect that we
observe above for the L1:L2 interaction is in the same range as
that of other mechanisms that have been shown to down-
regulate HDAC8, such as Zn2+ binding to the L2 loop and
phosphorylation of Ser39.11,13,26,27 The latter has been linked
to cellular regulation of HDAC8, where the activity of the
phosphorylated Ser39p and the mimicking mutant Ser39Glu is
2−6-fold less than that of the wild-type.27
The above results show that there are substrate-speciﬁc
contributions to the eﬀects of the mutations and that the
charge-altering mutations in the L1 and L2 loops are not
independent. Hence, the L1:L2 interaction is an important
component within the catalytic cycle of HDAC8. The explicit
inﬂuence on the kon, koff, and kcat rates is hidden in the (kcat/Km)
ratio, but we consistently see a rescue eﬀect by swapping the
charges on both loops, supporting our hypothesis that this
mechanism has a direct inﬂuence on the catalytic cycle. Note
that the residues mutated are not conserved, while a direct
interaction between the L1 and L2 loop has not been observed
before.
A detailed analysis of the MD and interactions present in the
three mutants would shed further light on the enzymatic
mechanism. Unfortunately, the sampling issues in such MD
simulations would be worse for the mutations as compared to
the wild-type, since certain states are predicted to be
depopulated. Achieving converged sampling thus seems out
of reach for such mutants. We therefore developed an
alternative approach to further bridge the experimental and
theoretical results, wherein the mutation is performed in silico.
Speciﬁcally, as shown in Supporting Information, mutating
Lys33 to Glu leads to a depopulation of the f2 state due to its
higher estimated free energy (Figure S3). Hence, our
experimental data supports the MD simulations, thereby
substantiating our hypothesis.
Enzymatic Function of the Dynamic Loop Interac-
tions. The catalytic cycle of HDAC8 involves at least three
steps, including binding of substrate, cleaving of the acetylated
lysine, and release of the products. Characterization of the
interconversions between these states during catalysis is central
to both understanding the underlying mechanism of HDAC8
and facilitating development of novel inhibitors of HDACs.
The structure of an inactive mutant of HDAC8 bound to a
cleavable substrate (PDB code 2V5W) has been previously
determined, and we will assume that this structure largely
represents a substrate binding state. A particular feature of this
structure is that the binding rail adopts the ‘in’ conformation,
forming hydrogen bonds with the substrate, there being no
obvious contacts between the L1 loop and the triple Asp repeat
of the L2 loop. Moreover, the L2 loop is structured in the
binding state with electron density for both backbone and side-
chains (Figure 1b).
Our simulations suggest that the L1 loop conformations and
dynamic interactions are able to steer the structure of the L2
loop and thereby inﬂuence the conformational sampling of the
binding rail. Only in the free form is there an eﬀective sampling
of the binding conformation of the L2 loop (Figure 2b), where
speciﬁcally in the f3 state the binding rail frequently samples
the ‘in’ conformation. When the distal part of L2 interacts with
L1, it traps the binding rail in the ‘out’ state. Conversely, when
there is no interaction with the L1 loop, the binding rail can
dynamically sample the ‘in’ conformation, i.e., a binding state.
We therefore hypothesize that the observed microkinetic
processes, in particular the L1:L2 interaction, are able to tune
the binding rail availability, hence tuning enzymatic activity.
■ CONCLUSIONS
Based on our MD simulations we propose a model in which
dynamic interactions of the L1 and L2 loops steer the behavior
of the binding rail of HDAC8 and should thus be regarded as
part of the catalytic process of the enzyme. Informed by these
simulations we designed mutations that interfere with this
interaction and were able to show, using two diﬀerent assays,
that this interaction has an eﬀect on the activity of the enzyme.
Moreover, it has been shown that zinc binding to a second
site at the distal L2 loop down regulates the enzyme. In the
structure where this site is occupied by zinc it is clear that the
Asp87−89 residues are not available to form salt-bridges with
the L1 loop. The mechanism proposed here helps to explain
this allosteric down regulation. Interestingly, the regions that
we have identiﬁed to be important for catalytic activity of
HDAC8 were also recently shown to be important in HDAC3,
where two binding partners are needed for activation.19 In the
recently published crystal structure of HDAC3, the activating
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binding partners clamp the interface adjacent to the L1 and L2
loop. This clamping yields a structure of HDAC3 similar to that
of HDAC8, possibly allowing for a similar L1:L2 interaction
and allosteric mechanism. A similar feature can also be
observed in HDAC2, where a recent crystal structure revealed
a more helical L2 loop, but a longer L1 loop, again allowing for
interloop interactions.28
Our theoretical work on the atomistic scale has yielded a
hypothesis we have been able to substantiate using biochemical
experiments on the macroscopic scale. Therefore, the
mechanism we propose furnishes a conceptual platform by
means of which one can rationalize the inﬂuence of L1 and L2
dynamic interactions on enzymatic activity of HDAC8 and
possibly other HDACs.
■ METHODS
Unbiased MD Simulations. The ﬁrst set of unbiased MD
simulations were performed using GROMACS 4.5.3,29−32 the
AMBER99SB-ILDN33 force ﬁeld, and TIP3P water. Five missing
residues in 1T69 were initially modeled using Modeller 9.09.34 The
solvated systems consisted of ∼57 000 atoms. 0.9 nm cutoﬀs were used
for electrostatic and van der Waals interactions and the particle mesh
Ewald (PME) method was applied for long-range electrostatics.35 We
used an extensive equilibration protocol, where each system was
simulated for 5 ns in an NVT ensemble followed by 5 ns in an NpT
ensemble during which we applied positional restraints of 1000 kJ
mol−1 nm−2 on heavy atoms of the protein and increased the
temperature. All production runs were performed in an NpT ensemble
using a Nose−́Hover thermostat at 300 K, an isotropic Parrinello−
Rahman pressure coupling and periodic boundary conditions. The
neighbor list was updated every 5 steps using 2 fs integration time
steps while keeping bonds involving hydrogens and heavy atoms
constrained using the P-LINCS algorithm.36 The topology for SAHA
was generated using AmberTools 1.5 with the RESP methodology
after geometry optimization at the B3LYP 6-31G* level using ORCA
2.8.0.37 Protonation states of histidines were calculated using the H++
server38 and the protonation states of histidines 142 and 143 close to
the catalytic site were taken from (ref 16) as protonated on the δ
nitrogen.
Analysis of backbone angles was done in VMD 1.9.39 Data was
analyzed using GROMACS, VMD 1.9, and MATLAB (MathWorks).
Sequence similarities and structure similarity Z-score of crystal
structures were obtained from the Dali server.40 Secondary structure
analysis was done using STRIDE.41 Protein structures were rendered
in PyMOL 1.4.1 (Schrödinger LLC).
The Anton20,21 production simulation was run in the NpT
ensemble with the same force ﬁeld and water model as the
GROMACS simulations. 1.1 nm cutoﬀs were used for short-range
interactions, and a 64 × 64 × 64 PME mesh was used for long-range
electrostatic interactions. A Berendsen thermostat and barostat42 were
applied to maintain 300 K and 1 bar as the simulation temperature and
pressure, respectively.
Protein Expression. HDAC8 was expressed as described
elsewhere.43 In brief, Escherichia coli codon-optimized coding sequence
of HDAC8 wild-type was obtained from GenScript (Piscataway, USA)
in a pET-29b+ vector containing an N-terminal His-NusA-tag44
separated from the HDAC8 coding sequence by a linker containing a
speciﬁc TEV cleavage site. Mutations were introduced by the
Quikchange protocol using codon-optimized primers. Wild-type and
mutant constructs were expressed using BL21(DE3) cells in 1 or 2 L
of LB medium at 21 °C overnight. Cells were harvested, resuspended
in lysis buﬀer [50 mM Tris pH 8.0, 3 mM MgCl2, 500 mM KCl, 5 mM
β-mercaptoethanol, 5 mM imidazole, 5% glycerol, 0.25% IGEPAL, 1
tablet of complete protease inhibitor (Roche) per 50 mL, traces of
DNase I (Roche), and lysozyme (Sigma)], before lysis through
sonication and subsequent centrifugation of the lysate at 25 000 g for
45 min. Puriﬁcation over a ﬁrst Ni-NTA column (GE Healthcare)
using an imidazole gradient (5−200 mM) was followed by dialysis into
cleavage buﬀer (50 mM Tris pH 8.0, 150 mM KCl, 5 mM β-
mercaptoethanol, 5% glycerol) and cleavage by His-tagged TEV-
protease. Cleaved HDAC8 was separated from the His-NusA-tag, the
TEV-protease and nonspeciﬁc contaminants by passage through a
second Ni-NTA column. The ﬂow-through was pooled, concentrated,
and subjected to a gel ﬁltration column (S75, GE Healthcare) in gel-
ﬁltration buﬀer (50 mM Tris pH 8.0, 150 mM KCl, 1 mM TCEP, 5%
glycerol). Samples were concentrated and ﬂash frozen in liquid N2.
Fluorogenic HDAC8 Activity Assay. Trichostatin A (TSA) was
purchased from Enzo Life Sciences and porcine pancreatic trypsin
(type IX-S) from Sigma. Boc-Lys(Ac)-7-amino-4-methylcoumarin
(MAL) was synthesized according to the literature.45 The in vitro
HDAC assay used is based on a homogeneous ﬂuorogenic HDAC
assay.46 Aliquots were prepared for HDAC8 wild-type and each
mutant to yield a 0.4, 1, and 2 μM ﬁnal concentration in the total
reaction volume of 60 μL in assay buﬀer (50 mM Tris pH 8.0, 137
mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1 mg/mL BSA). MAL
substrate solution of 50 mM in DMSO was diluted in assay buﬀer and
added to the enzyme solution to yield a ﬁnal concentration of 250 μM
in the reaction volume.
The HDAC8:MAL solution was incubated at 25 °C for 30 or 60
min, after which 50 μL of the reaction solution was pipetted on a 96-
well white NBS microplate, where the wells had been preloaded with
50 μL developer solution (10 mg/mL trypsin and 4 μM TSA in assay
buﬀer). The microplate was left for 30 min at ambient temperature
before the ﬂuorescence was measured on a BMG FLUOstar Optima
plate reader with excitation at 380 nm and emission at 460 nm.
Activities for diﬀerent reaction times and concentrations were
compared to the wild-type enzyme and averaged as summarized in
Table 1. Errors were estimated as the root-mean-square deviation of
the activity measured in the six assays for each mutant (two time
points and three concentrations).
The kcat/Km for the wild-type enzyme was determined using
substrate concentrations of 25, 50, 100, 200, 400, and 600 μM and an
enzyme concentration of 400 nM. Reactions were incubated for 15, 30,
and 45 min (Figure S4). The error given represents the 2σ interval for
the χ2 ﬁtting.
Real-Time NMR p53 Assay. The 21 amino acid peptide used as
substrate in the assay was purchased from PEPCEUTICALS
(Leicestershire, UK) with the sequence based on the N-terminal tail
of p53: GSHLKSKKGQSTSRHK-K(Ac)-LMFK, where K(Ac)
denotes acetylated lysine, which corresponds to the Lys382 position
in p53. The substrate was dissolved in NMR assay buﬀer (25 mM Tris
pH 8.0, 137 mM NaCl, 2.7 mM KCl, and 1 mM MgCl2) and 10% (v/
v) D2O was added.
The substrate concentration was determined by NMR using a
potassium acetate standard. Enzyme was added to start the reaction
with a ﬁnal enzyme concentration of 500 nM in a total volume of 550
μL for each NMR sample. 1D 1H NMR spectra were recorded (each
231 s) over a time course of typically 16−24 h. Substrate and product
peaks were integrated for each spectrum to yield the progression of
substrate to product conversion.
Michaelis−Menten diﬀerential equations were solved with known
starting conditions for a grid of kcat/Km values yielding a ﬁrst estimate
of kcat/Km by ﬁtting a ﬁrst-order polynomial through the minimum of
the χ2 surface. The ﬁt was reﬁned by calculating χ2 on a line
perpendicular to ﬁrst determined kcat/Km. kcat/Km was taken
corresponding to χ2min and reﬁned again. Errors reported represent
the 1σ conﬁdence interval assuming a 5% uncertainty in measuring the
NMR signal, based on the signal-to-noise ratio of the spectra. See
Supporting Information and Figure S5.
NMR spectra were recorded on a Bruker Avance 500 (Karlsruhe,
Germany). Data were processed using the TopSpin software (Bruker).
Analysis was done using MATLAB (Mathworks).
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